GE Healthcare forms strategic alliance with cardiovascular genomic diagnostic company, CardioDx
GE Healthcare, the healthcare business of GE (NYSE: GE) and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease. Building on the alliance, the GE Healthymagination Fund (www.healthymaginationfund.com), a new equity fund that makes investments in highly promising healthcare technology companies, has invested $5 million in CardioDx as part of a Series D round that the fund is leading. The alliance between the two companies aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare. This marks the first investment for the HealthymaginationFund. Otherfinancialtermswerenotdisclosed.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.